Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Pharma
BMS, Merck, Amgen and more face near-term generic woes: Leerink
As patent expirations near for many of the world’s top drugmakers, companies will need to be diligent about M&A, according to a new Leerink report.
Fraiser Kansteiner
Nov 13, 2024 10:57am
Novo, Lilly lost value in Q3 while BMS, Gilead and Sanofi surged
Nov 8, 2024 5:00am
As new drugs deliver, BMS explores further efficiency moves
Oct 31, 2024 10:27am
BMS partner Zai Lab eyes China filing for KarXT after trial win
Oct 29, 2024 1:59pm
Life sciences giants back thrombosis awareness campaign
Oct 14, 2024 9:46am
BMS' schizophrenia gem Cobenfy was salvaged from the scrapheap
Oct 7, 2024 3:00am
